Short-period-induced hypertension could improve tumor-to-nontumor ratios of radiolabeled monoclonal antibody.
This study was undertaken to find optimum period of hypertensive treatment for the improvement of tumor targeting of 111In-labeled monoclonal antibody. Angiotensin II was infused into tumor-bearing mice at an infusion rate of 2.0 micrograms/kg/min determined by the dose-finding study. The infusion was continued for up to 72 h, and biodistribution of 111In-DTPA-A7, a murine IgG1, was observed 72 h postinjection. Tumor-to-nontumor ratios were best improved with the infusion for 0.5-3 h. However, with the longer infusion, the effect deteriorated by the increase of nontumor uptakes, and body-weight loss became remarkable. It could be concluded that hypertensive treatment for a short period could be safely performed to benefit targeting of radiolabeled monoclonal antibody.
Kinuya
S
S
Department of Nuclear Medicine, Kanazawa University School of Medicine, Japan. kinuya@med.kanazawa-u.ac.jp
Yokoyama
K
K
Yamamoto
W
W
Konishi
S
S
Shuke
N
N
Aburano
T
T
Watanabe
N
N
Takayama
T
T
Michigishi
T
T
Tonami
N
N
D000804:Angiotensin II / Q000494:pharmacology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics; D005260:Female; D006973:Hypertension / Q000139:chemically induced / Q000378:metabolism*; D007205:Indium Radioisotopes; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D016719:Radioimmunodetection; D014018:Tissue Distribution
D000911:Antibodies, Monoclonal; D007205:Indium Radioisotopes; D000804:Angiotensin II